Retatrutide for Weight Loss in Raleigh, NC

What is retatrutide?

Retatrutide is a once-weekly subcutaneous injectable developed by Eli Lilly. It is a triagonist, meaning it activates three distinct receptor pathways involved in metabolic regulation. GLP-1 receptor activation supports appetite reduction and glucose homeostasis. GIP receptor activation supports additional metabolic signaling. GCG receptor activation influences energy expenditure and fat metabolism.

This triple receptor engagement differentiates retatrutide from dual agonists like tirzepatide (GIP/GLP-1) and single agonists like semaglutide (GLP-1 only).

Regulatory status and clinical context

Retatrutide is not FDA-approved. It is an investigational compound currently in Phase 3 clinical trials (Eli Lilly's TRIUMPH program, including TRIUMPH-1, TRIUMPH-2, TRIUMPH-3, and TRIUMPH-4).

At RegenesisMD, any discussion of retatrutide takes place in an educational and investigational context. Dr. Vaidya reviews the current status of available compounds and discusses which options are appropriate for each patient based on their individual health profile and goals. Patients should ask Dr. Vaidya directly about the current regulatory status at the time of their consultation, as this may have changed.

How it differs from semaglutide and tirzepatide

• Semaglutide: activates the GLP-1 receptor; FDA-approved products include Ozempic for type 2 diabetes and Wegovy for chronic weight management.
• Tirzepatide: activates GIP and GLP-1 receptors; FDA-approved products include Mounjaro for type 2 diabetes and Zepbound for chronic weight management.
• Retatrutide: activates GIP, GLP-1, and GCG receptors and remains investigational; it is not FDA-approved.

The addition of glucagon receptor agonism is the key pharmacological distinction. Glucagon receptor activation is associated with increased energy expenditure in preclinical and early clinical data.

For information about the clinic's medical weight loss program, semaglutide, and tirzepatide, visit those service pages.

Published Phase 2 findings and limitations

In the Phase 2 trial published in NEJM (Jastreboff et al., 2023), 338 adults with obesity or overweight were randomized to placebo or retatrutide at doses of 1 mg, 4 mg, 8 mg, or 12 mg once weekly. At 48 weeks the trial reported the following mean weight reductions:

• 1 mg group: 8.7% mean weight reduction
• 4 mg group: 17.1% mean weight reduction
• 8 mg group: 22.8% mean weight reduction
• 12 mg group: 24.2% mean weight reduction
• Placebo group: 2.1% mean weight reduction

These are Phase 2 results from one manufacturer-funded trial. They do not represent the completed regulatory evidence package. Phase 3 data from larger, longer trials is needed to characterize long-term cardiovascular outcomes, thyroid effects, and other safety signals.

Safety considerations

The safety profile was described as similar to other incretin-based therapies, with nausea, diarrhea, vomiting, and constipation as the most common adverse events, mostly mild to moderate and concentrated in the early dose escalation period.

Discuss current weight-management options

If you are interested in learning about the current weight loss options available at RegenesisMD, including FDA-approved options, off-label options, and the current investigational landscape, your provider will review your individual health history and discuss which protocols may be appropriate for your goals.

Frequently Asked Questions

What is retatrutide and how does it work?

Retatrutide is an investigational triple-hormone receptor agonist that simultaneously activates GIP, GLP-1, and GCG receptors. This differentiates it from dual agonists like tirzepatide (GIP/GLP-1) and single agonists like semaglutide (GLP-1 only). It is currently in Phase 3 clinical trials and is not FDA-approved.

Is retatrutide FDA approved?

No. Retatrutide is not FDA-approved as of the date of this content. It is in Phase 3 clinical trials (Eli Lilly's TRIUMPH program). Patients should ask Dr. Vaidya directly about the current regulatory status at the time of their consultation, as this may have changed.

What did the Phase 2 trial show?

The Phase 2 trial published in NEJM in 2023 (Jastreboff et al.) showed dose-dependent mean weight reductions of up to 24.2% at 48 weeks in the highest dose group, compared to 2.1% in the placebo group. These are Phase 2 results from one manufacturer-funded trial. Phase 3 confirmatory data is ongoing.

How is retatrutide different from semaglutide or tirzepatide?

Semaglutide is a single GLP-1 agonist. Tirzepatide is a dual GIP/GLP-1 agonist. Retatrutide is a triple GIP/GLP-1/GCG agonist. The addition of glucagon receptor agonism is the key pharmacological distinction. Both semaglutide and tirzepatide are FDA-approved for weight management. Retatrutide is not.

Can I start retatrutide at RegenesisMD right now?

Dr. Vaidya reviews the current status of available compounds and discusses which options are appropriate for each patient based on their individual health profile and goals. Patients should ask Dr. Vaidya directly about availability and current trial status at the time of their consultation.

Medical disclaimer

Retatrutide is an investigational compound that has not received FDA approval for any indication. Phase 2 clinical trial data has been published; Phase 3 trials are ongoing. This content is for educational purposes only and does not represent a recommendation to use retatrutide. Individual results vary. Schedule a consultation with our clinical team, MD to discuss current weight loss treatment options and whether investigational protocols may be appropriate for your health goals.